Carter's plays defense with a poison pill to prevent a hostile takeover
Source: SeekingAlpha
2025-09-24 06:51:58 ET
More on Carter's
- Carter's Q2 Results Were Not Good, And Tariffs' Impact Is Still Incoming
- Carter's: Going Against The Market's Narrative As Sales Turn
- Carter's, Inc. (CRI) Q2 2025 Earnings Conference Call Transcript
- Carter’s targets price increases and store optimization amid $125M–$150M annual tariff headwind
- U.S. import tariffs to impact Carter's profits going ahead; shares tank
Read the full article on Seeking Alpha
For further details see:
Carter's plays defense with a poison pill to prevent a hostile takeover
Carter's Inc.
NASDAQ: CRI
CRI Trading
-0.66% G/L:
$34.57 Last:
308,977 Volume:
$34.98 Open:
CRI Latest News
CRI Stock Data
$1,400,327,089
35,718,911
0.4%
98
N/A
Retail - Discretionary
Consumer Discretionary
US
Atlanta
